Citation Tools
PDFRegular and young investigator award abstracts
Clinical trials completed
279 Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC impacts local-regional control and overall survival
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 279 Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC impacts local-regional control and overall survival